Journal of Diabetes Research / 2015 / Article / Tab 3

Review Article

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Table 3

Mean differences of weight and the rank of GLP-1 RAs on weight loss in comparison with placebo.

TreatmentWeight control
MD (95% CI)SUCRARank

EX10BID−1.92 (−2.61, −1.24)0.982981
EX2QW−0.92 (−2.01, 0.13)0.762283
EX5BID−0.86 (−1.90, 0.20)0.750204
LIR0.60.46 (−0.80, 1.71)0.3882910
LIR0.90.56 (−2.48, 3.68)0.428988
LIR1.2−0.31 (−1.44, 0.81)0.584416
LIR1.8−0.98 (−1.94, −0.02)0.788912
Insulin2.60 (1.56, 3.62)0.1286311
Met−0.49 (−2.45, 1.46)0.633185
SU3.37 (2.29, 4.48)0.0302113
Sitagliptin0.28 (−1.09, 1.67)0.424659
TZD2.67 (1.28, 4.07)0.1128712

Note: EX5BID: exenatide 5 μg twice daily; EX10BID: exenatide 10 μg twice daily; EX2QW: exenatide 2 mg once weekly; LIR0.6: liraglutide 0.6 mg once daily; LIR0.9: liraglutide 0.9 mg once daily; LIR1.2: liraglutide 1.2 mg once daily; LIR1.8: liraglutide 1.8 mg once daily; SU: sulfonylureas; TZD: thiazolidinediones; Met: metformin.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.